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Abstract
During May and June 2008, 84 Danish army recruits were tested
for faecal carriage of extended-spectrum b-lactamase (ESBL)-
producing and AmpC b-lactamase-producing bacteria. Three
ESBL-producing (CTX-M-14a) Escherichia coli isolates, two
AmpC-producing (CMY-2) E. coli isolates and one AmpC-pro-
ducing (CMY-34) Citrobacter freundii isolate were detected. Two
of the CTX-M-14a E. coli isolates had similar pulsed-ﬁeld gel
electrophoresis and multilocus sequence typing proﬁles, indicat-
ing the same origin or transmission between the two army
recruits. The blaCTX-M-14a genes were transferable to an E. coli
recipient. These commensal bacteria therefore constitute a res-
ervoir of resistance genes that can be transferred to other
pathogenic bacteria in the intestine.
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Extended-spectrum b-lactamases (ESBLs) are increasingly
being reported in Europe. In human patients, ESBLs are
mostly found in Escherichia coli isolates causing community-
acquired infections; in particular, CTX-M enzymes are
increasingly being detected [1]. As ESBL-producing bacteria
have also been detected in food and animals, there might be a
possibility of transfer of the ESBL-producing bacteria, or their
resistance genes, from animals to humans, either by direct
contact or via the food chain [2–8]. It is therefore of interest
to look for faecal carriage of ESBL-producing or AmpC-pro-
ducing bacteria in healthy humans in the community. How-
ever, only a few studies have investigated this [9–12].
The aim of the present study was to screen for ESBL-pro-
ducing or AmpC-producing bacteria among Danish healthy
humans not recruited through the healthcare system, and to
characterize the resistant isolates in relation to virulence
genes and transferability of the resistance genes.
Between 20 May and 17 June 2008, 84 of 120 army
recruits (70.0%) from one military barracks in Denmark
agreed to participate in the study. Each person mailed a fae-
cal sample to the Statens Serum Institut (SSI) and ﬁlled in a
questionnaire with information on gender, age, medications,
gastrointestinal symptoms and diseases, travel activities, food
consumption and animal contact. The Scientiﬁc Ethics Com-
mittee for the Copenhagen and Frederiksberg municipalities
approved the protocol prior to the investigation (KF 01-006/
02). Only eight of the 84 recruits were women, and the
median age was 21 years (range: 18–31 years). The recruits
had been resident in the barracks for 6 months for training,
but went home each weekend.
Half a gram of faeces was suspended in 5 mL of saline
(0.9%). One hundred microlitres of the diluted faecal sample
was spread on two SSI Enteric agar plates (SSI Diagnostika,
Hillerød, Denmark), one supplemented with 2 mg/L cefotax-
ime and the other with 2 mg/L ceftazidime. Both plates were
incubated in ambient air for 18 h at 35C. Presumptive
third-generation cephalosporin-resistant Enterobacteriaceae
were subcultured on 5% blood agar plates (SSI Diagnostika).
Only one colony per sample was investigated further. The
isolates were identiﬁed with API 20E (BioMe´rieux, Marcy-
l’Etoile, France) and retested for susceptibility to cefotaxime
and ceftazidime by Etest (AB Biodisk, Solna, Sweden).
ESBL and/or AmpC phenotypes were tested with the
NeoSensitabs double-disk method according to the manufac-
turer’s guidelines (Rosco Diagnostica A/S, Taastrup, Den-
mark). On the basis of the obtained phenotype, the presence
of TEM, SHV, CTX-M, OXA, MOX, CIT, DHA, ACC, EBC
and FOX b-lactamase genogroups was investigated by PCR
[13] (F. Hansen, unpublished data). Positive amplicons were
sequenced. E. coli isolates were typed by pulsed-ﬁeld gel elec-
trophoresis and multilocus sequence typing [14,15]. MICs
were determined for chloramphenicol, ciproﬂoxacin, genta-
micin, nalidixic acid, streptomycin, sulphamethoxazole, tetra-
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cycline and trimethoprim (Trek Diagnostic, East Grinstead,
UK). Data were interpreted with the EUCAST breakpoints.
The phylogenetic background (A, B1, B2, D) of the E. coli
isolates was determined by triplex PCR with three DNA
markers [16]. The results obtained allowed classiﬁcation of
the isolates into the four major E. coli phylogenetic lineages
or as non-typeable isolates according to Gordon et al. [17].
The E. coli isolates were investigated for the extraintestinal
pathogenic E. coli (ExPEC)-related virulence genes kpsMII,
papA, papC, iutA, sfaS, focG, afa and hlyD (unpublished data).
In vitro matings were obtained according to Trobos et al.
[15]. The recipient strain was a rifampin-resistant mutant of
E. coli K-12 (MG1655). The selective plates used were Luria–
Bertani agar (Sigma-Aldrich, Brøndby, Denmark) supple-
mented with: (i) 2 mg/L cefotaxime and 50 mg/L rifampin; (ii)
2 mg/L cefotaxime; or (iii) 50 mg/L rifampin.
From faecal samples of six male army recruits, ﬁve E. coli
isolates and one Citrobacter freundii isolate were obtained
(one isolate per person) (Table 1). Three of the ﬁve E. coli
isolates had an ESBL phenotype and were positive for CTX-
M-14a. The two other E. coli isolates had an AmpC pheno-
type and were positive for CMY-2. The C. freundii isolate had
an AmpC phenotype and was positive for CMY-34 (Table 1).
Two of the ESBL-producing E. coli isolates (3807X08 and
3827X08) had identical pulsed-ﬁeld gel electrophoresis, mul-
tilocus sequence typing and resistance proﬁles. Both isolates
were obtained from faecal samples sent within 1 week; it is
therefore likely that these isolates had the same origin or
that there had been transmission between these two army
recruits. Only one of the recruits had been in contact with
animals. CTX-M-14 has also been detected in faecal samples
from healthy humans in Spain, indicating a community reser-
voir of this enzyme in other countries [10–12].
Two isolates (3786Z08 and 3823Z08) contained the iutA
gene, whereas the other E. coli isolates were negative for
all virulence genes tested. None of the ﬁve E. coli isolates
was an ExPEC isolate according to the molecular deﬁnition
of ExPEC isolates [18]. Urinary tract infections are most
often associated with phylogroup B2 and, to some extent,
with phylogroup D. One of the tested E. coli isolates
belonged to phylogroup D, whereas none of them
belonged to phylogroup B2 (Table 1). Rates of transfer of
phenotypic resistance to the E. coli and C. freundii donors
are presented in Table 1. The blaCTX-M-14a genes had a
high transfer rate.
The six army recruits had not been hospitalized within
1 month before the faecal samples were taken, and nor had
they travelled abroad within 3 months prior to sampling. All
had been eating meat (pork, poultry meat and beef) on a
regular basis (Table 1). Two of the six army recruits had T
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been treated with a penicillin compound (penicillin and dicl-
oxacillin, respectively) within 6 months before sampling. Such
treatment might have selected for the resistant E. coli iso-
lates. Five recruits had been in contact with companion ani-
mals or hunting animals, but not with food animals, within
the last week before sampling.
It was not possible to screen the meat that the recruits
had been eating or the animals that they had been in contact
with for ESBL/AmpC-producing bacteria, but a common
source seems likely.
The investigated E. coli isolates were not virulent, and the
ESBL-producing isolates were susceptible to all of the non-
b-lactam antibiotics tested, but, because of their excellent
ability to transfer resistance genes, they may act as donors
of ESBL genes for other more virulent and resistant E. coli
isolates.
In summary, even though the ESBL prevalence in hospitals
is low in Denmark as compared with southern European
countries, six of the 84 studied Danish army recruits (7%)
harboured ESBL-producing or AmpC-producing bacteria in
their gut, which indicates a human faecal reservoir in the
community.
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